The market for mRNA vaccines has experienced a surge fueled by the global rollout of the COVID-19 vaccines, and the potential of mRNA technology in public health opens a new frontier in medical ...
Product Performance – potency and dosing: Cryogenic transmission electron microscopy (Cryo-TEM) revealed more uniform, solid-core particles. Increased lipid and RNA concentrations can enhance in vivo ...
Introduced to the public in the form of the COVID vaccines, mRNA technology is based on decades of research. Still in the early phases, the next-generation of these therapeutics will expand beyond ...
RNA-based therapeutics are transforming medicine, but scaling production efficiently remains a challenge, particularly the cost-intensive in vitro transcription (IVT) step. Join this webinar to ...
The "mRNA Therapeutics Contract Development & Manufacturing Organization - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for mRNA ...
BioNTech maintains strong cash reserves (€15.85B) despite widening losses as COVID revenues decline and R&D expenses increase. BNT327 (PD-L1/VEGF-A bispecific) advances to Phase 3 trials, but shares ...
Bayer has opened a new legal front in the long-running battles over COVID-19 vaccine technology, suing several major ...
On May 31, Bloomberg reported that the FDA recently granted Moderna Inc. (NASDAQ:MRNA) a narrower approval for its next-generation COVID-19 vaccine. The authorization is now limited to adults aged 65 ...
French biotech OSE Immunotherapeutics is taking charge of a new project aimed at fast-tracking nanodrug development and creating new mRNA therapeutics, with 1.3 million euros ($1.47 million) in ...
At the Mayo Clinic, Dr. Guifang Zhao is leading a new generation of regenerative medicine therapies that combine the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback